Domo signs strategic collaboration agreement with AWS for AI solutions
Director Sanam Parikh of Tharimmune, Inc. (NASDAQ:THAR), a micro-cap biotech company with a market capitalization of $3.57 million, recently purchased 1,000 shares of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, the shares were bought at a price of $1.45 per share, for a total transaction value of $1,450. The purchase price represents a premium to the current trading price of $1.31, though analysts maintain a $5.00 price target for the stock. Following the transaction, Parikh directly owns 1,770 shares of Tharimmune. InvestingPro analysis shows the company holds more cash than debt on its balance sheet, though its overall financial health score remains weak. Additional insights are available with an InvestingPro subscription.
In other recent news, Tharimmune, Inc. has undergone significant leadership changes, appointing Sireesh Appajosyula as the new Chief Executive Officer and Vincent LoPriore as the Executive Chairman of the Board. These changes follow Randy Milby’s resignation as CEO and board member due to personal reasons, with a settlement agreement in place for Milby. Concurrently, James Gordon Liddy has joined the Board of Directors, bringing national security expertise to the company. Tharimmune has also expanded its board with the addition of Clay Kahler and Gary Stetz, enhancing its focus on growth and governance. In terms of product development, the company reported promising results from a Phase 1 study of TH104, a drug designed for opioid exposure prophylaxis, which could potentially accelerate its regulatory pathway. The U.S. FDA has indicated that Tharimmune may submit a New Drug Application for TH104 without additional clinical trials. These developments reflect Tharimmune’s ongoing efforts to advance its clinical programs and strengthen its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.